PolyMedix, Inc.
http://polymedix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PolyMedix, Inc.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Deals of the Week Watches Parkinson’s In Prime Time
Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.
Deals of the Week Watches Parkinson’s In Prime Time
Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.
Cellceutix Buys Mid-Stage Antibiotic Brilacidin On The Cheap
With brilacidin developer PolyMedix having filed for bankruptcy, Cellceutix will acquire the company’s assets for $2.1 million in cash and 1.4 million shares of stock.
Company Information
- Other Names / Subsidiaries
-
- PolyMedix Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice